PHILADELPHIA, Pa. -- At the 228th national meeting of the American Chemical Society held this week in Philadelphia, researchers from Harvard Medical School report that they have found a way to produce novel aminocoumarins -- antibiotics that can help in the fight against drug-resistant bacteria.
The development of bacterial resistance to antibiotics is a major public health concern. Currently, doctors have precious few weapons to fight strains such as methicillin-resistant Staphylococcus aureus (MRSA). Though some of these super bugs are sensitive to aminocoumarins, theres a catch. Low solubility, poor absorption and distribution, and the inability to penetrate the bacterial cell wall, make these compounds less than ideal antibiotics.
Now, Christopher T. Walsh, the Hamilton Kuhn professor of biological chemistry and molecular pharmacology at Harvard Medical School, and colleagues report a method that can be used to generate potentially hundreds of aminocoumarin variants. This approach allows the controlled variation of all parts of the aminocoumarin scaffold in the search to create antibiotics with tailored and improved properties, said Walsh.
In an ironic twist, the method developed by the researchers exploits bacterial enzymes. Caren Freel Meyers, a research fellow in Walshs lab, has used an alphabet soup of proteins from Streptomyces to make an enzymatic production line that adds, stepwise, different chemical moieties to the backbone of coumermycin A1, a member of the aminocoumarin family of antibiotics.
Starting with this coumermycin scaffold, Freel Meyers used the enzyme CouL to add one or two amino groups, then CouM to add a sugar component called L-noviose. The enzyme CouP was found to add methyl groups to the CouM products, and NovN was used to add one or two carbamoyl moieties to methylated CouP product variants. By playing mix-and-match with enzymes and CouL substrates that make up the coumermycin A1 backbone, multiple designs can be rolled off the production line. In a proof of principle experiment, Freel Meyers generated a library of nine coumermycin variants. Three of these compounds have been produced in sufficient quantity for detailed analysis, and they are currently undergoing biological evaluation.
Aminocoumarins are inhibitors of bacterial type II topoisomerases, enzymes that untwist and unknot DNA. Without these topoisomerases bacteria cannot replicate. For this reason, fluoroquinolone antibiotics, such as ciprofloxacin and levofloxacin, which are potent inhibitors of type II topoisomerases, have found widespread use. However, the emergence of resistant bacterial strains has renewed interest in the aminocoumarin novobiocin, which is one of the few drugs available that is effective against MRSA.
The sugar moieties attached to the coumermycin backbone are thought to bind to and inactivate the essential bacterial topoisomerase DNA gyrase. By modifying the noviose substituents Freel Meyers and colleagues hope to develop more effective gyrase inhibitors. By modifying other components of the backbone the researchers hope to turn these inhibitors into potent antibiotics, ones that are more soluble, have better pharmacokinetics, and more readily penetrate their bacterial targets.
Source: Harvard Medical School
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.